Strategic out-licensing: maximising the value of your portfolio

female colonis employee smiling

Strategic out-licensing: maximising the value of your portfolio

In the pharmaceutical industry, breaking into the UK market presents a unique set of challenges; it can be a complex maze of regulatory processes, pricing complexities, and market access hurdles, where local expertise becomes indispensable.

That’s why the importance of finding a trusted out-licensing partner cannot be understated. Do you want to discover your full potential in the UK pharmaceutical market? Read on to discover the power of out-licensing, and how renowned leaders in valued-added medicines, Colonis, can ensure your medicine’s growth in the thriving UK market.

What is out-licensing?

Out-licensing is a strategic practice in which pharmaceutical companies grant external partners the rights to license or distribute their product in a new market. This allows collaboration between pharmaceutical companies, enabling them to combine their expertise and resources to unlock new opportunities and expand their reach.  At Colonis, we harness our out-licensing partnerships to deliver high-quality, value-added medicines to new markets, certifying future growth and ensuring continued progress.

The benefits of out-licensing

Out-licensing offers a host of advantages for pharmaceutical companies seeking a streamlined path to commercialisation in a new market. One key benefit is the ability to reduce costs and share risks. Through strategic partnerships, companies can collaboratively fund the journey from drug development to market approval, alleviating financial burdens and optimising portfolio value.

Out-licensing opens up new markets outside of a company’s core domestic territory without the risks and costs of setting up market access and distribution infrastructure.

By partnering with experts in global markets, companies can reduce the dependency on a single product or market focus and enhance their resilience, whilst also extending the life cycle of a drug by delivering value-added medicines to patients in new markets.

Out-licensing Products to the UK: How Colonis can help

For pharmaceutical companies outside the UK, making a successful transition into the market can be a daunting task. This is where collaborating with Colonis can offer significant benefits. We are experts in navigating the UK pharmaceutical landscape, with a deep understanding of the UK regulatory processes, pricing, reimbursement, and market access.

Here’s how we support you:

Local expertise: Colonis have been established in the UK for over 15 years; our expert team has a thorough understanding of the complexities of the UK market. We have a proven track record of licensing medicines from other markets into the UK, developing long-term successful partnerships, providing invaluable guidance and support throughout the process of commercialising value-added medicines and more.

Local regulations: At Colonis, we ensure that your product aligns with UK regulatory guidelines, thanks to our intimate knowledge of the Medicines and Healthcare products Regulatory Agency (MHRA) and UK pharmaceutical regulatory system, attained through our track record of achieving authorisations for value-added medicines.

Pricing and reimbursement: Our experts here at Colonis can help you navigate the UK’s complex reimbursement mechanisms as a result of our profound understanding of the UK drug tariff system. Setting the right price and securing reimbursement are critical aspects of pharmaceutical success in the UK. As such, we develop appropriate pricing strategies, optimising value for our partners.

Market access and commercialisation: In the competitive UK pharma market, ensuring that your products reach the right patients is paramount. Out-licensing with Colonis extends your reach by providing you with access to our established networks within the UK, allowing you to maximise the potential of your product. We offer tailored market access strategies that are specifically crafted to align with your product and portfolio. From securing patient pathway adoption to orchestrating marketing and sales efforts and efficient supply chain management, our in-depth knowledge of the UK marketplace maximises commercial opportunities to ensure value-added medicines are available to healthcare professionals and, most importantly, reach the patients who need them the most.

Out-licensing with Colonis: a partnership for success

Entering the UK pharmaceutical market can be challenging, but out-licensing with a trusted partner can bring numerous advantages that help ensure products reach the UK market successfully, ultimately improving patient outcomes and expanding your global pharmaceutical footprint.

Through a strategic partnership with Colonis, you have access to the expertise, guidance, and support you need to successfully out-license your products in the UK. We understand the uniqueness of the UK market, and we’re here to ensure that your products reach the patients who need them most.

Want to find out more about partnering opportunities? We’d love to hear from you. Visit our contact page for more information.

GB-CPL-0-036

December 2023

Stay up to date, connect with us on Social Media

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being directed to an external website for which Colonis is not responsible.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the external website.

You are now leaving

You are now leaving the Colonis website and being directed to an external website for which Colonis is not responsible.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the external website.